IRF7 and neoplasm: Similarly, activation of Type I IFN/IRF7 axis is critical for immunological tumor dormancy in breast cancer, an adaptive and protective mechanism that malignant cells adopt to survive stress conditions of the TME and to drive resistance to chemotherapies that preferentially target proliferating cells [240,241].